Global Troponin Market Size and Trends
The global troponin market was valued at US$ 1.38 Bn in 2023 and is expected to reach US$ 3.55 Bn by 2031, growing at a compound annual growth rate (CAGR) of 12.5% from 2024 to 2031.
Figure 1. Global Troponin Market Share (%), by Region, 2024
Figure 2. Global Troponin Market Share (%), by Product Type, 2023
Global Troponin Market Trends:
- Consolidation among key players: The global troponin market has been witnessing significant consolidation trends among key players in recent years. Major companies have been acquiring smaller competitors to expand their product portfolios and geographical reach. For instance, Roche Diagnostics, develops innovative products and services, acquired Spark Biomedicals, a leading U.S.-based wearable neurostimulation solutions, in 2022 to enhance its cardiac biomarker testing solutions. Similarly, Abbott Laboratories, an American multinational medical devices took over Abbott Rapid Diagnostics, a global manufacturer of rapid point-of-care diagnostic tests in 2021, which strengthened Abbott's diagnostics business. Such consolidation moves allow companies to combine complementary technologies and leverage synergies.
- Integration of AI and machine learning into troponin testing: The integration of AI and machine learning into troponin testing is having a profound impact on the global troponin market. Advancements in these technologies have enabled the development of high sensitivity troponin assays that can detect even minuscule elevation in troponin levels during the early stages of a suspected heart attack. These high sensitivity assays leverage machine learning algorithms during their design to identify unique biomarkers and develop tests that are able to distinguish normal ranges from negligible increases associated with acute coronary syndrome. For example, researchers from the National Institutes of Health (NIH), 2020, worked with several diagnostic companies to create an artificial intelligence model trained on troponin test results from over 30,000 patients. The model was able to identify subtle troponin patterns that indicated heart issues better than traditional methods.
- Shift towards the development of panel-based testing: The shift towards panel-based testing trend is having a significant impact on the global troponin market. Panel-based testing involves testing for multiple biomarkers simultaneously using a single patient sample, as opposed to performing individual tests sequentially. This provides several advantages over individual biomarker testing. This trend towards panel-based testing is driving considerable demand for troponin assays that can be integrated into biomarker panels. According to recent data published by the European Society of Cardiology, the share of troponin tests being performed as part of cardiac biomarker panels increased from 36% in 2018 to 46% in 2021 across European hospitals. Particularly, high sensitivity troponin assays that can reliably detect even small changes in troponin levels have become the assay of choice for most cardiac biomarker panels. Their inclusion enables more accurate rule-in and rule-out of acute myocardial infarction.
U.S.: 
U.K. : 
India : 
